{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-005656","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2026-07-20T20:27:24+00:00","discovered_at":"2026-07-20T20:28:02.280420+00:00","generated_at":"2026-07-20T20:28:06.926217+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sunshine Biopharma enters $4M ATM equity facility with Aegis Capital","bullets":["Up to $4M of common stock may be sold at-the-market through Aegis Capital as exclusive agent.","Aegis receives 3.0% commission on gross proceeds plus expense reimbursement.","Shares issued under existing S-3 shelf (File No. 333-284142) effective Jan 15, 2025.","No obligation to sell; Company controls timing and volume via placement notices.","Agreement can be terminated by either party per its terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-005656","json":"https://secwatch.observer/filing/0001683168-26-005656.json","markdown":"https://secwatch.observer/filing/0001683168-26-005656.md","text":"https://secwatch.observer/filing/0001683168-26-005656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/0001683168-26-005656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T20:28:06.926217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}